tiprankstipranks
Mangalam Organics Ltd (IN:MANORG)
:MANORG
India Market
Want to see IN:MANORG full AI Analyst Report?

Mangalam Organics Ltd (MANORG) AI Stock Analysis

0 Followers

Top Page

IN:MANORG

Mangalam Organics Ltd

(MANORG)

Select Model
Select Model
Select Model
Neutral 57 (OpenAI - 5.2)
Rating:57Neutral
Price Target:
₹486.00
▲(0.15% Upside)
Action:ReiteratedDate:04/09/26
The score is primarily held back by weak profitability and deteriorating cash flow (including negative operating cash flow), despite solid revenue growth and improved gross/operating margins. Technicals are mixed with short-term strength but longer-term weakness, and valuation (P/E 24.261) appears only moderately attractive without dividend yield support.
Positive Factors
Improved Gross Margin & Revenue Growth
A large jump in gross margin alongside revenue growth indicates structural improvement in pricing, product mix, or input-cost management. Sustained higher gross margins provide durable capacity to cover operating costs and fund reinvestment, supporting margin sustainability and operational resilience over the medium term.
Negative Factors
Negative Operating Cash Flow
Negative operating cash flow and a steep decline in free cash flow are a structural concern: they limit internal funding for capex, working capital, and debt service. Persistent cash-generation weakness forces reliance on external financing and constrains strategic investments, raising liquidity and execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Gross Margin & Revenue Growth
A large jump in gross margin alongside revenue growth indicates structural improvement in pricing, product mix, or input-cost management. Sustained higher gross margins provide durable capacity to cover operating costs and fund reinvestment, supporting margin sustainability and operational resilience over the medium term.
Read all positive factors

Mangalam Organics Ltd (MANORG) vs. iShares MSCI India ETF (INDA)

Mangalam Organics Ltd Business Overview & Revenue Model

Company Description
Mangalam Organics Limited manufactures, supplies, and exports terpene chemicals and synthetic resins in India. It operates through Terpene Operations and Synthetic Resin Operations segment. The company offers terpene products, including camphor, c...
How the Company Makes Money
Mangalam Organics makes money primarily by manufacturing and selling terpene-based specialty chemicals to business customers. Its core revenue stream is product sales—most notably synthetic camphor—and other pine/terpene derivatives and related sp...

Mangalam Organics Ltd Financial Statement Overview

Summary
Revenue grew 7.39% and gross margin improved sharply (48.40% in 2025 vs 22.89% in 2024), but profitability remains weak (net margin 2.38%, ROE 4.29%) and cash generation is a key risk with operating cash flow turning negative and free cash flow growth at -329.40%.
Income Statement
65
Positive
Balance Sheet
58
Neutral
Cash Flow
52
Neutral
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue5.78B5.30B4.94B4.93B4.91B3.38B
Gross Profit2.59B2.57B1.13B701.20M1.47B1.72B
EBITDA783.42M589.13M390.38M-24.27M924.25M1.28B
Net Income242.13M125.97M42.86M-272.25M537.43M847.79M
Balance Sheet
Total Assets7.29B6.24B4.85B5.06B5.60B3.11B
Cash, Cash Equivalents and Short-Term Investments411.72M189.27M20.19M12.79M12.78M343.55M
Total Debt3.52B2.72B1.73B1.90B2.12B243.11M
Total Liabilities4.21B3.30B2.05B2.30B2.56B596.26M
Stockholders Equity3.09B2.93B2.81B2.76B3.04B2.52B
Cash Flow
Free Cash Flow-769.42M-751.15M327.48M361.57M-1.84B-27.60M
Operating Cash Flow-281.34M-78.44M727.23M769.23M-841.04M262.79M
Investing Cash Flow-381.05M-670.47M-395.09M-407.80M-995.25M-281.47M
Financing Cash Flow673.44M736.26M-325.52M-355.77M1.83B22.66M

Mangalam Organics Ltd Technical Analysis

Technical Analysis Sentiment
Positive
Last Price485.25
Price Trends
50DMA
414.96
Positive
100DMA
445.09
Positive
200DMA
489.92
Negative
Market Momentum
MACD
8.35
Negative
RSI
69.73
Neutral
STOCH
73.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MANORG, the sentiment is Positive. The current price of 485.25 is above the 20-day moving average (MA) of 407.27, above the 50-day MA of 414.96, and below the 200-day MA of 489.92, indicating a neutral trend. The MACD of 8.35 indicates Negative momentum. The RSI at 69.73 is Neutral, neither overbought nor oversold. The STOCH value of 73.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:MANORG.

Mangalam Organics Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
63
Neutral
₹3.49B22.440.25%30.76%88.92%
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
60
Neutral
₹5.85B22.241.23%-5.04%-26.70%
58
Neutral
₹5.91B36.573.46%-9.55%
58
Neutral
₹26.51B14.050.09%15.19%9.27%
57
Neutral
₹3.92B24.2627.49%151.36%
46
Neutral
₹7.16B-2,425.331.07%-19.76%-92.63%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:MANORG
Mangalam Organics Ltd
458.10
59.65
14.97%
IN:AARTISURF
Aarti Surfactants Ltd.
411.90
-12.03
-2.84%
IN:CHEMCON
Chemcon Speciality Chemicals Ltd
161.45
-28.75
-15.12%
IN:FAIRCHEMOR
Fairchem Organics Ltd
568.35
-240.87
-29.77%
IN:JAYAGROGN
Jayant Agro-Organics Limited
194.90
-37.96
-16.30%
IN:ROSSARI
Rossari Biotech Ltd
478.75
-188.69
-28.27%

Mangalam Organics Ltd Corporate Events

CRISIL Reaffirms Mangalam Organics’ Rs 397-Crore Bank Facility Ratings on Watch
Apr 14, 2026
Mangalam Organics Ltd has announced that CRISIL Ratings has reviewed and reaffirmed the company’s credit ratings on its bank facilities totaling Rs. 397 crore. The long-term rating remains at CRISIL BBB+ and the short-term rating at CRISIL A...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 09, 2026